+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
RNA Therapy Market by Technology, Indication, End User - Global Forecast 2025-2030- Product Image
RNA Therapy Market by Technology, Indication, End User - Global Forecast 2025-2030- Product Image
Sale

RNA Therapy Market by Technology, Indication, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 4968964
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The RNA Therapy Market grew from USD 2.18 billion in 2023 to USD 2.60 billion in 2024. It is expected to continue growing at a CAGR of 22.38%, reaching USD 8.98 billion by 2030.

RNA therapy, a pivotal segment of genetic medicine, involves manipulating RNA to treat genetic disorders by repairing or altering protein expression. Its scope encompasses therapies like antisense oligonucleotides, RNA interference, and mRNA-based treatments. The pressing necessity for RNA therapy arises from its potential to treat diseases at the genetic root, offering targeted and personalized medicine, which is critical in addressing unmet medical needs such as rare genetic disorders and challenging conditions like cancer.

Its applications are broad, encompassing disease areas like oncology, cardiovascular, metabolic disorders, and infectious diseases. End-use scope involves hospitals, research institutes, and biopharmaceutical companies, where the emphasis is on developing safe and effective delivery mechanisms. Market growth is primarily influenced by increasing investments in genetic research, supportive regulatory landscapes, and significant advancements in nanotechnology to enhance delivery systems. Opportunities abound in the advent of CRISPR-Cas systems coupled with RNA technologies, enabling precise gene editing. Additionally, expanding partnerships between academia and industry for innovative drug development and a growing biopharmaceutical pipeline highlight potential for robust expansion.

However, challenges include the high cost of research and development, complex regulatory hurdles, and delivery issues associated with RNA instability and immune response triggers. To overcome these, focusing on the development of novel delivery technologies like lipid nanoparticles and exosomes for improved stability and bioavailability is essential. Innovations can also thrive by integrating artificial intelligence in drug discovery processes to expedite RNA therapy development. Understanding regional market demands and fostering collaborations can further enhance competitiveness. Researching resilient synthetic RNA molecules might mitigate some intrinsic limitations of current RNA-based approaches. As the RNA therapy market is still evolving, it necessitates a dynamic strategy emphasizing continuous innovation, regulatory adaptability, and technology integration to ensure sustainable growth.

Understanding Market Dynamics in the RNA Therapy Market

The RNA Therapy Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing understanding of the role of RNA in disease pathology
    • Heightened demand for personalized medicine
    • Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
  • Market Restraints
    • High costs associated with RNA therapy development processes
  • Market Opportunities
    • Increased investments by governments and private organizations in research and development activities
    • Pipelined clinical trials of RNA-based therapeutics
  • Market Challenges
    • Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines

Exploring Porter’s Five Forces for the RNA Therapy Market

Porter’s Five Forces framework further strengthens the insights of the RNA Therapy Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the RNA Therapy Market

External macro-environmental factors deeply influence the performance of the RNA Therapy Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the RNA Therapy Market

The RNA Therapy Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the RNA Therapy Market

The RNA Therapy Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Arbutus Biopharma Corporation, NeuBase Therapeutics, Inc., Moderna, Inc., Arcturus Therapeutics Holdings Inc., BioNTech SE, AstraZeneca PLC, Arrowhead Pharmaceuticals, Inc., Nordic Nanovector ASA, MiNA Therapeutics Limited, Silence Therapeutics PLC, Eli Lilly and Company, Cartesian Therapeutics, Inc., Novartis AG, Sirnaomics, Inc., F. Hoffmann-La Roche AG, ProQR Therapeutics N.V., Cenix BioScience GmbH, Nutcracker Therapeutics, Inc., Laronde, Triplet Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Deep Genomics, Biogen Inc., GSK PLC, Benitec Biopharma Limited, Sanofi S.A., and Novo Nordisk A/S.

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Technology
    • Enabled Technologies
      • Inhibition
      • Labeling
      • Linear amplification
      • Microarrays
      • Purification
      • qRT-PCR
    • Enabling Technologies
      • RNA Antisense Technologies
        • MicroRNA
        • Small interfering RNA
      • RNA Interference Technologies
  • Indication
    • Cancer
    • Cardiovascular
    • Genetic Disorders
    • Infectious Diseases
    • Kidney Diseases
    • Metabolic Disorders
    • Oncology
    • Retinal Diseases
  • End User
    • Academic Research
    • Diagnostics
    • Drug Discovery & Development
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing understanding of the role of RNA in disease pathology
5.1.1.2. Heightened demand for personalized medicine
5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
5.1.2. Restraints
5.1.2.1. High costs associated with RNA therapy development processes
5.1.3. Opportunities
5.1.3.1. Increased investments by governments and private organizations in research and development activities
5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
5.1.4. Challenges
5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
5.2. Market Segmentation Analysis
5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
5.5. Client Customization
6. RNA Therapy Market, by Technology
6.1. Introduction
6.2. Enabled Technologies
6.2.1. Inhibition
6.2.2. Labeling
6.2.3. Linear amplification
6.2.4. Microarrays
6.2.5. Purification
6.2.6. qRT-PCR
6.3. Enabling Technologies
6.3.1. RNA Antisense Technologies
6.3.1.1. MicroRNA
6.3.1.2. Small interfering RNA
6.3.2. RNA Interference Technologies
7. RNA Therapy Market, by Indication
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular
7.4. Genetic Disorders
7.5. Infectious Diseases
7.6. Kidney Diseases
7.7. Metabolic Disorders
7.8. Oncology
7.9. Retinal Diseases
8. RNA Therapy Market, by End User
8.1. Introduction
8.2. Academic Research
8.3. Diagnostics
8.4. Drug Discovery & Development
9. Americas RNA Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific RNA Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa RNA Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics
List of Figures
FIGURE 1. RNA THERAPY MARKET RESEARCH PROCESS
FIGURE 2. RNA THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. RNA THERAPY MARKET DYNAMICS
TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 56. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 57. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 58. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 59. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 60. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 63. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 64. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 65. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 78. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 83. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 84. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 85. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 86. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 89. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 90. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 91. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 92. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 95. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 96. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 97. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 98. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 101. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 107. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 108. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 109. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 127. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 132. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 133. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 137. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 138. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 139. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 143. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 144. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 145. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 149. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 150. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 151. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 152. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 160. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 162. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 163. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 164. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 167. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 168. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 169. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 170. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 174. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 175. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 176. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 179. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 180. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 181. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 182. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 183. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. GERMANY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. GERMANY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 186. GERMANY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 187. GERMANY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 188. GERMANY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 189. GERMANY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 194. ISRAEL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. ISRAEL RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 196. ITALY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. ITALY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 198. ITALY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 199. ITALY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 200. ITALY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 201. ITALY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. NORWAY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 215. NORWAY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 216. NORWAY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 217. NORWAY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 218. NORWAY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. NORWAY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 220. POLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. POLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 222. POLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 223. POLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 224. POLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. POLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. QATAR RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. QATAR RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 228. QATAR RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 229. QATAR RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 230. QATAR RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 231. QATAR RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 234. RUSSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 235. RUSSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 236. RUSSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 237. RUSSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 240. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 242. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SPAIN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 251. SPAIN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 252. SPAIN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 253. SPAIN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 254. SPAIN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. SPAIN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 261. SWEDEN RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. TURKEY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. TURKEY RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 270. TURKEY RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 271. TURKEY RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 272. TURKEY RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 273. TURKEY RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 279. UNITED ARAB EMIRATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 282. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 284. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM RNA THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 287. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the RNA Therapy market, which are profiled in this report, include:
  • Arbutus Biopharma Corporation
  • NeuBase Therapeutics, Inc.
  • Moderna, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • BioNTech SE
  • AstraZeneca PLC
  • Arrowhead Pharmaceuticals, Inc.
  • Nordic Nanovector ASA
  • MiNA Therapeutics Limited
  • Silence Therapeutics PLC
  • Eli Lilly and Company
  • Cartesian Therapeutics, Inc.
  • Novartis AG
  • Sirnaomics, Inc.
  • F. Hoffmann-La Roche AG
  • ProQR Therapeutics N.V.
  • Cenix BioScience GmbH
  • Nutcracker Therapeutics, Inc.
  • Laronde
  • Triplet Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Deep Genomics
  • Biogen Inc.
  • GSK PLC
  • Benitec Biopharma Limited
  • Sanofi S.A.
  • Novo Nordisk A/S

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 2.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.98 Billion
Compound Annual Growth Rate22.3%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

RNA Interference Technology Market by Type, Therapeutics, Application - Global Forecast 2025-2030 - Product Image

RNA Interference Technology Market by Type, Therapeutics, Application - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route of Administration (Intrathecal, Intravenous), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antisense And RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular, Genetic), By Route of Administration (Intrathecal, Intravenous), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 130 Pages
  • Global
From
RNA-based Therapeutics Market - Product Image

RNA-based Therapeutics Market

  • Report
  • 200 Pages
  • Global
From
RNA Analysis/Transcriptomics Market by Product, Technology, Application, End-User - Global Forecast 2025-2030 - Product Image

RNA Analysis/Transcriptomics Market by Product, Technology, Application, End-User - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Ribose-Nucleic Acid (RNA)-based Therapeutics Market Report 2024 - Product Image

Ribose-Nucleic Acid (RNA)-based Therapeutics Market Report 2024

  • Report
  • 175 Pages
  • Global
From

About the RNA Therapy Market

RNA therapy is a form of gene therapy that uses RNA molecules to treat or prevent diseases. It is a type of genomics-based therapy that works by introducing genetic material into cells to modify their behavior. RNA therapy can be used to treat a variety of diseases, including cancer, neurological disorders, and infectious diseases. It has the potential to be used to treat genetic disorders, as well as to modify the expression of genes in order to improve the effectiveness of existing treatments. RNA therapy works by introducing genetic material into cells, which can then be used to modify the expression of genes. This can be done by introducing a gene that produces a therapeutic protein, or by introducing a gene that silences a gene that is causing a disease. RNA therapy can also be used to modify the expression of existing genes, which can be used to improve the effectiveness of existing treatments. RNA therapy is an emerging field of genomics-based therapy, and is being explored by a number of companies. Examples of companies in the RNA therapy market include Moderna, BioNTech, and Arcturus Therapeutics. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.